VERV(Delisted)
Verve TherapeuticsยทNASDAQ
--
--(--)
VERV fundamentals
Verve Therapeutics (VERV) expects to report earnings on Aug 14, 2025, with estimated revenue of 4.52M (YoY -32.46%), and EPS at -0.69 (YoY -16.95%).
Revenue estimate / YoY
4.52M
-32.46%
EPS estimate / YoY
-0.69
-16.95%
Report date
Aug 14, 2025
EPS
Revenue
Revenue & Expenses
VERV has released its 2025 Q1 earnings report, with revenue of 32.98M, reflecting a YoY change of 479.03%, and net profit of -31.03M, showing a YoY change of 36.32%. The Sankey diagram below clearly presents VERV's revenue sources and cost distribution.
Key Indicators
Verve Therapeutics (VERV) key financial stats and ratios, covering profitability, financial health, and leverage.
Verve Therapeutics (VERV)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Verve Therapeutics (VERV)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Verve Therapeutics (VERV)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Verve Therapeutics (VERV) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Verve Therapeutics (VERV) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield
You can ask Aime
No Data
